MYC and leukemia: It was observed that HHT and ibrutinib were found to have a synergistic inhibitory effect that prevented proliferation, induced apoptosis, and arrested cell cycle at the G0/G1 phase in MV4-11 and MOLM-13 leukemia cells.[76] The results indicate that the primary mechanisms underlying the combination effect involve modulating the AKT pathway, Bcl-2 family, STAT5/Pim-2/C-Myc pathway, activating p21WAF1/CIP1, and suppressing the CCND/CDK complex protein.